Sign up
Pharma Capital

VentriPoint Diagnostics brings in over C$1mln from placing; closes second tranche

The group issued around 2.43mln units at C$0.21 each for gross proceeds of $511,499.94
VentriPoint has developed a suite of applications for all major heart diseases and imaging modalities

Heart-imaging specialist VentriPoint Diagnostics Ltd (CVE:VPT) has closed the second and final tranche of its previously announced placing, raising more than C$511,000.

The group issued around 2.43mln units at C$0.21 each for gross proceeds of $511,499.94. In total, the firm raised gross proceeds of C$1,011,499.94 under the placing.

Proceeds will be used for sales and marketing, development and general working capital, Ventripoint said. Each unit consists of one Ventripoint share, and one-half of a share warrant. Each whole warrant will entitle the bearer to buy one further share at US$0.34 each for two years after the issue.

Chief executive Dr George Adams subscribed for 1.5mln units, the company said in the regulatory filing.

Why Invest In VentriPoint Diagnostics Ltd.? Read More Here

Register here to be notified of future VPT Company articles
View full VPT profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.